Metrics to compare | 94E | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship94EPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.8x | −11.1x | −0.4x | |
PEG Ratio | 0.09 | 0.15 | 0.00 | |
Price/Book | 2.9x | 5.1x | 2.6x | |
Price / LTM Sales | - | 12.0x | 3.1x | |
Upside (Analyst Target) | - | 75.5% | 49.6% | |
Fair Value Upside | Unlock | −8.0% | 7.1% | Unlock |
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.